BIO-013077-01 is a novel and potent antagonist of the TGFbeta family type I receptors, Alk5 and/or Alk4.

BIBF0775, a 6-substituted indolinone analog, is a novel, potent and selective inhibitor of transforming growth factor β (TGFβ) type I receptor (Alk5) with an IC50 of 34 nM.

ITD-1 is a selective inhibitor of TGF-β signaling (IC50 = 0.85 μM); exhibits little or no inhibition of activin, Wnt or BMP signaling pathways.

SM16 is a novel and potent Type I TGF-β signaling inhibitor, also a ALK5/ALK4 kinase inhibitor with Kis of 10 and 1.5 nM, respectively.

SB-505124 HCl, the hydrochloride salt of SB505124, is a selective inhibitor of TGFβR (TGF-β Receptor type I receptor) for ALK4, ALK5 (activin receptor-like kinase) with potential anticancer activity.

Vactosertib HCl (formerly EW-7197; EW7197) is a highly potent, selective, and orally bioavailable inhibitor of the TGF-β receptor ALK4/ALK5 with anticancer and immunomodulatory effects.

LSKL is a potent and peptide-based inhibitor of Thrombospondin TSP-1 with the potential to be used for treating hypertrophic scar.

BMP signaling agonist sb4 is a novel and potent enzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist.

Vactosertib (formerly EW-7197; TEW-7197) is a highly potent, selective, ATP-competitive and orally bioavailable inhibitor of the TGF-β receptor ALK4/ALK5 (activin receptor-like kinase) with potential anticancer activity.

LY3200882 is a next generation, ATP competitive, potent, highly selective small molecule inhibitor of TGF-β receptor type 1 (TGFβRI).